Information Provided By:
Fly News Breaks for August 2, 2019
ABMD
Aug 2, 2019 | 07:50 EDT
As previously reported, Morgan Stanley analyst David Lewis downgraded Abiomed to Equal Weight from Overweight, stating that the issues pressuring its results "look more structural than transient" following weakness that has persisted for two quarters. As Impella seems to be transitioning to a more mature market outlook, other key catalysts remain two to three years away, said Lewis, who cut his price target on Abiomed shares to $215 from $325.
News For ABMD From the Last 2 Days
There are no results for your query ABMD